Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • About us
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
    • Media
      • Image library
      • Video library
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • Events
      • General meetings
  • Contact
    • Career
Skip to content
Regulatory
23 August 2023

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
AllAnnual reportInterim ReportNewsNewsletterPress releaseYear end reportRegulatory posts
23 August 2023 Scandion Oncology – Interim Report Q2 2023 Download Presentation Webcast Workbook
17 August 2023 Data from PANTAX trial to be presented at ESMO Congress 2023 Download Presentation Webcast Workbook
16 August 2023 Invitation to Scandion Oncology webcast and conference call August 23, 2023 Download Presentation Webcast Workbook
26 May 2023 Scandion Oncology – Interim Report Q1 2023 Download Presentation Webcast Workbook
26 April 2023 Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors Download Presentation Webcast Workbook
11 April 2023 Scandion Oncology – Notice convening the Annual General Meeting Download Presentation Webcast Workbook
28 March 2023 Scandion Oncology – Annual Report 2022 Download Presentation Webcast Workbook
22 February 2023 Scandion Oncology – Q4 & year-end report 2022 Download Presentation Webcast Workbook
19 January 2023 Scandion Oncology A/S: Scandion Oncology receives favorable opinion from the European Patent Office on Composition of Matter Patent-application for lead compound SCO-101 Download Presentation Webcast Workbook
16 November 2022 Interim Report 1 July – 30 September 2022 Download Presentation Webcast Workbook
28 October 2022 Scandion Oncology Announces Results of Extraordinary General Meeting Download Presentation Webcast Workbook
13 October 2022 Scandion Oncology – Notice convening an Extraordinary General Meeting Download Presentation Webcast Workbook
  1. Frontpage

About us

  • About us
  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Media
    • Image library items
    • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Contact us

Scandion Oncology A/S
Symbion
Fruebjergvej 3
2100 Copenhagen
Denmark

Phone: +45 38 10 20 17
info@scandiononcology.com

Media and Investor relations:
Email: ir@scandiononcology.com
Phone: +45 29 60 35 32

Follow us


Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.